A new study identified key factors that can impact the long-term weight loss of patients with obesity who were prescribed injectable semaglutide or liraglutide for the treatment of type 2 diabetes or obesity.
Key factors that impact long-term weight loss in patients prescribed GLP-1 RA medications." ScienceDaily. ScienceDaily, 13 September 2024. <www.sciencedaily.com
Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic ... A register-based study identified three distinct BMI trajectory groups among patients with newly diagnosed type 2 diabetes. In a four-year follow-up, most patients followed a stable trajectory ...
Semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes, according to new research. Semaglutide is ... Being overweight or having obesity, weight that is higher than what is considered healthy for an individual's height, is a major risk factor for high blood pressure. A healthy diet, more ...Will EEG Be Able to Read Your Dreams? The Future of the Brain Activity Measure as It Marks 100 Years
Diabetes Obesity Fitness Diseases And Conditions Chronic Illness Wounds And Healing Pharmacology
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
JPMorgan says this new player in the GLP-1 market could rally 45%This GLP-1 drug could emerge as the next big treatment and rival key competitors.
Read more »
Healthy Returns: More than 50 million privately insured adults could be eligible for GLP-1 drugsA large swath of insured Americans could be eligible for a popular class of weight loss and diabetes drugs. Meanwhile, Apple announces new health features.
Read more »
Healthy Returns: More than 50 million privately insured adults could be eligible for GLP-1 drugsA large swath of insured Americans could be eligible for a popular class of weight loss and diabetes drugs. Meanwhile, Apple announces new health features.
Read more »
Over 900 Claim GLP-1 Drugs Like Ozempic Caused Severe Gastrointestinal InjuriesA sweeping new lawsuit filed by over 900 people alleges that GLP-1 drugs like Ozempic and Mounjaro caused them severe gastrointestinal injuries, even after discontinuing use. Lawyers representing the plaintiffs argue that existing warnings about these side effects were insufficient and failed to adequately describe the potential harm.
Read more »
Beyond The Sticker Shock: Why GLP-1s Might Save More Than They CostI’m an internationally recognized consultant and author with over 25 years of experience in the field of strategy development and execution, business model design, and market analysis.
Read more »
New research shows psychological effects from the use of GLP-1 drugs.GLP-1 agonists may improve the disease course for a host of neurological and psychiatric disorders tied to inflammation, providing relief to millions of patients.
Read more »